Claims
- 1. A method of ameliorating one or more symptoms of Gram positive bacterial or mycobacterial sepsis in a subject comprising administering to the subject a therapeutically effective amount of an antibody having the same immunoreactivity as an antibody produced by ATCC Accession No. HB11364 (28C5) or an immunoreactive fragment thereof.
- 2. The method of claim 1, wherein the antibody is the antibody produced by ATCC Accession No. HB11364 (28C5).
- 3. The method of claim 1, wherein the antibody is comprised of F(ab′)2 portions.
- 4. The method of claim 1, wherein the therapeutically effective amount is 0.1 to 20 milligrams per kilogram body weight per day.
- 5. The method of claim 1, wherein the method further comprises administering to said patient a bactericidal amount of an antibiotic.
- 6. The method of claim 5, wherein said antibiotic is an anti-bacterial agent effective against Gram-positive bacteria.
- 7. The method of claim 1 wherein the method further comprises administering to the subject a TNF blood concentration-reducing amount of an anti-TNF antibody.
- 8. The method of claim 1 wherein the subject displays symptoms of one or more of the following: adult respiratory distress syndrome, disseminated intravascular coagulation, renal failure and hepatic failure.
- 9. A method of ameliorating Gram positive bacterial or my cobacterial sepsis in a subject comprising administering to the subject a therapeutically effective amount of an antibody having the same immunoreactivity as an antibody produced by ATCC Accession No. HB44 (63D3) or an immunoreactive fragment thereof.
- 10. The method of claim 9, wherein the antibody is the antibody produced by ATCC Accession No. HB44 (63D3).
- 11. The method of claim 9, wherein said monoclonal antibody is comprised of F(ab′)2 portions of anti-CD14 antibody molecules.
- 12. The method of claim 9 wherein said therapeutically effective amount is 0.1 to 20 milligrams per kilogram body weight per day.
- 13. The method of claim 9 wherein said method further comprises substantially simultaneously administering to said patient a bactericidal amount of an antibiotic.
- 14. The method of claim 13 wherein said antibiotic is an anti-bacterial agent effective against Gram-positive bacteria.
- 15. The method of claim 9 wherein the method further comprises administering to the subject patient a TNF blood concentration-reducing amount of an anti-TNF antibody.
- 16. The method of claim 9 wherein the subject displays symptoms of one or more of the following: adult respiratory distress syndrome, disseminated intravascular coagulation, renal failure and hepatic failure.
- 17. A method of ameliorating one or more symptoms of Gram positive bacterial or mycobacterial sepsis in a subject comprising administering to the subject, a therapeutically effective amount of an antibody that inhibits binding of Gram-positive toxigenic cell wall components to CD14, and inhibits secretion of tumor necrosis factor by cells of the monocyte macrophage lineage, thereby treating the sepsis.
- 18. The method of claim 17 wherein the antibody is a monoclonal antibody that competitively inhibits the binding of the toxigenic cell wall components to CD14.
- 19. The method of claim 17 wherein the antibody is produced by hybridoma ATCC HB44 or ATCC HB11364 or a host cell containing a polynucleotide encoding a 63D3 or 28C5 antibody.
- 20. The method of claim 17 wherein the Gram-positive bacteria is Staphylococcus aureus.
- 21. The method of claim 17 wherein the Gram-positive bacteria is selected from the group consisting of Group A and Group B Streptococci.
- 22. The method of claim 17 wherein the Gram-positive bacteria is Streptococcus pneumoniae.
- 23. The method of claim 17 wherein the mycobacterium is Mycobacterium tuberculosis.
STATEMENT OF GOVERNMENT RIGHTS
[0001] This invention was supported in part by grant Nos. A1115136, GM28485 HL23586, and GM37696 from the U.S. National Institute of Health. The United States Government may have a significant interest in this invention.
Continuations (3)
|
Number |
Date |
Country |
Parent |
09742599 |
Dec 2000 |
US |
Child |
10206382 |
Jul 2002 |
US |
Parent |
09099957 |
Jun 1998 |
US |
Child |
09742599 |
Dec 2000 |
US |
Parent |
08307931 |
Sep 1994 |
US |
Child |
09099957 |
Jun 1998 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
07990378 |
Dec 1992 |
US |
Child |
08307931 |
Sep 1994 |
US |